On Air Now
Capital Breakfast with Jono and Emily 6am - 10am
9 November 2016, 10:04
Drugs giant Pfizer announces it's closing its Havant site by 2020 putting 270 jobs at tisk as production moving to Belgium
Pfizer UK spokesperson has released this
"Following a review of our global supply network Pfizer proposes to exit two of its UK supply facilities.
The proposed decision to exit these sites is not a reflection of the excellent work performed by our colleagues. It is important to note that these proposals are in no way related to the result of the Brexit decision.
Our priority at this time is to support affected colleagues and where possible to mitigate against job losses resulting from these proposals.
Both sites will work to different proposed closure timings, the Hospira UK Ltd (Aseptic Services) Compounding site at Park Royal in North London is proposed to exit by May 2017, and the Pfizer packaging and distribution site in Havant is proposed to exit by the end of 2020.
Pfizer proposes transferring work now done at its Havant, UK, facility to its facility in Puurs, Belgium. This proposed decision is not a reflection of the excellent work performed by our colleagues at Havant, or in any way related to the Brexit decision, but is part of our regular evaluation of our global supply network, to ensure it aligns its production capabilities with anticipated future demand, supports innovations that improve current manufacturing processes and the new products pipeline, and the efficiencies of consolidating operations into fewer locations.
As part of the integration of Hospira and Pfizer, a thorough evaluation was conducted and the decision to close the Hospira UK Ltd (Aseptic Services) Park Royal site in North London is because it is an aging facility which will require significant investment in the near future and due to the expiration of the building lease.
Over 270 colleagues are currently based at Pfizer's cold-chain packaging and distribution site at Havant. The North London site employs around 100 colleagues.
Pfizer is committed to delivering value for health services and patients globally, by ensuring the most efficient supply of medicines and vaccines to patients."